www.biopharminternational.com April 2019 BioPharm International eBook 27
Outsourcing Resources Business Developments
Monster
Ztudio
-
stock.adobe.com
Outsourcing Expansions
and Collaborations
CMOs and CDMOs continue to expand their
offerings and services in the biologics arena.
I
n early 2019, contract manufacturing organizations
(CMOs) and contract development and manufactur-
ing organizations (CDMOs) announced investments in
services and facilities, collaborations, and acquisitions.
The following highlights some of the latest CMO and
CDMO news.
ACQUISITIONS
CMOs and CDMOs made steps to grow their businesses
with acquisitions in the early part of 2019. Some of the
more noteworthy acquisitions include the following.
Thermo Fisher Scientific Inc. took a major step into the
viral vector manufacturing arena with the announced
purchase of Brammer Bio, a viral vector CDMO, with 600
employees and locations in Massachusetts and Florida.
The purchase agreement, announced in a March 24, 2019
press statement, is for approximately $1.7 billion in cash.
Brammer Bio will become part of Thermo Fisher's pharma
services business, which includes Patheon and Fisher
Clinical Services (1).
"Brammer Bio will be an exciting addition to our
pharma services business and will further strengthen
Thermo Fisher's leadership in serving pharma and bio-
tech customers," said Marc N. Casper, president and chief
executive officer of Thermo Fisher Scientific in the state-
ment. "Gene therapy is an area of increasing focus for our
customers and is fast-evolving given its potential to treat a
range of genetic disorders. The combination of Brammer
SUSAN HAIGNEY
